Sanofi (SNY N) Stock Overview

Engages in the research, development, manufacture, and marketing of therapeutic solutions. More details

SNY N fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 57.7% below our estimate of its fair value

Earnings are forecast to grow 16.9% per year

Risk Analysis

Shares are highly illiquid

Dividend of 5.36% is not well covered by earnings

Large one-off items impacting financial results

SNY N Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Sanofi Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sanofi
Historical stock prices
Current Share Price	€736.00
52 Week High	€1,016.40
52 Week Low	€730.01
Beta	0.28
1 Month Change	-12.90%
3 Month Change	-8.00%
1 Year Change	-26.62%
3 Year Change	-24.12%
5 Year Change	-29.23%
Change since IPO	9.43%

Recent updates

Shareholder Returns

	SNY N	MX Pharmaceuticals	MX Market
7D	0%	0.8%	0.2%
1Y	-26.6%	22.2%	15.6%

Return vs Industry: SNY N underperformed the MX Pharmaceuticals industry which returned 22.2% over the past year.

Return vs Market: SNY N underperformed the MX Market which returned 15.6% over the past year.

Price Volatility

Is SNY N's price volatile compared to industry and market?
SNY N volatility
SNY N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.1%
10% most volatile stocks in MX Market	6.1%
10% least volatile stocks in MX Market	2.6%

Stable Share Price: SNY N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine SNY N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	74,846	Belen Garijo Lopez	www.sanofi.com

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.

Sanofi Fundamentals Summary

How do Sanofi's earnings and revenue compare to its market cap?
SNY N fundamental statistics
Market cap	Mex$1.87t
Earnings (TTM)	Mex$97.09b
Revenue (TTM)	Mex$952.04b

19.1x

P/E Ratio

1.9x

P/S Ratio

Is SNY N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SNY N income statement (TTM)
Revenue	€47.35b
Cost of Revenue	€13.09b
Gross Profit	€34.26b
Other Expenses	€29.44b
Earnings	€4.83b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 30, 2026

Earnings per share (EPS)	4.02
Gross Margin	72.36%
Net Profit Margin	10.20%
Debt/Equity Ratio	24.9%

How did SNY N perform over the long term?

See historical performance and comparison

Dividends

5.4%

Current Dividend Yield

102%

Payout Ratio

Does SNY N pay a reliable dividends?

See SNY N dividend history and benchmarks

When do you need to buy SNY N by to receive an upcoming dividend?
Sanofi dividend dates
Ex Dividend Date	May 04 2026
Dividend Pay Date	Jun 03 2026
Days until Ex dividend	19 days
Days until Dividend pay date	11 days

Does SNY N pay a reliable dividends?

See SNY N dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/22 01:47
End of Day Share Price	2026/05/13 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sanofi is covered by 53 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
null null	Banco de Sabadell. S.A.

Sanofi (SNY N) Stock Overview

Rewards

Risk Analysis

Sanofi Competitors

Genomma Lab Internacional. de

GSK

Bristol-Myers Squibb

Chugai Pharmaceutical

Price History & Performance

Recent News & Updates

Sanofi Demonstrates Superiority Of Efdoralprin Alfa Over Standard-Of-Care Augmentation Therapy In Achieving Higher Functional Alpha-1 Antitrypsin Levels In Alpha-1 Antitrypsin Deficiency

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Announces Board and Committee Changes

Sanofi Approves Ordinary Annual Dividend, Payable on May 7, 2026

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Recent updates

Sanofi Demonstrates Superiority Of Efdoralprin Alfa Over Standard-Of-Care Augmentation Therapy In Achieving Higher Functional Alpha-1 Antitrypsin Levels In Alpha-1 Antitrypsin Deficiency

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Announces Board and Committee Changes

Sanofi Approves Ordinary Annual Dividend, Payable on May 7, 2026

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Sanofi Receives US Approval for Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children

Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike in Head-To-Head Study

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Sanofi Becomes Market Authorization Holder for Nuvaxovid in Canada

Sanofi Announces Lunsekimig Meets Primary And Key Secondary Endpoints In Phase 2 Respiratory Studies In Asthma And CRSwNP

Sanofi Announces EU Approval of Rezurock for Treatment of Chronic Graft-Versus-Host Disease

Sanofi Presents New Results from Amlitelimab Phase 3 Studies in Atopic Dermatitis

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

Sanofi Earns Breakthrough Therapy Designation in the Us for Venglustat for Type 3 Gaucher Disease

Sanofi, Annual General Meeting, Apr 29, 2026

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Sanofi's Rilzabrutinib Designates Breakthrough Therapy in the Us and Orphan Drug in Japan for the Treatment of Cold Autoimmune Hemolytic Anemia

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi (ENXTPA:SAN) completed the acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX).

Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease

Sanofi’s Rezurock Recommends for EU Approval by the CHMP to Treat Chronic Graft-vs-Host Disease

Sanofi Provides Earnings Guidance for the Year 2026

Sanofi Proposes Dividend for 2025

Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis

Sanofi Announces Approval of Myqorzo and Redemplo in China

Sanofi's Tzield Accepts for Priority Review in the Us for Young Children with Stage 2 Type 1 Diabetes

Sanofi (ENXTPA:SAN) agreed to acquire Dynavax Technologies Corporation (NasdaqGS:DVAX) for $1.9 billion.

Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis

Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases

Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Sanofi's Teizeild Recommends for EU Approval by the CHMP for Patients with Stage 2 Type 1 Diabetes

Sanofi Announces Positive Results from the pivotal LIBERTY- AFRS-AIMS Phase 3 Study

Sanofi Announces New Data from the Alphamedix-02 Phase 2 Study Evaluating Alphamedix

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Sanofi's Tzield Accepts for Expanded Review in the US for Stage 3 Type 1 Diabetes Through FDA Commission's National Priority Voucher Pilot Program

Sanofi's High-Dose Influenza Vaccine Demonstrates Superior Protection for Older Adults Against Hospitalization vs Standard-Dose

Sanofi Provides Update on Regulatory Review in the EU for Rezurock to Treat Chronic Graft-Vs-Host Disease

Sanofi's Wayrilz Recommends for Eu Approval by the CHMP to Treat Immune Thrombocytopenia

Sanofi Announces Positive Results from the ALPHAMEDIX-02 Phase 2 Study

Sanofi to Report Q3, 2026 Results on Oct 30, 2026

Sanofi Expands Patient Affordable Program by Offering Access to All Its Insulins for $35 Per Month in the US

Sanofi Announces its SAR446268 Receives US Fast Track Designation for Treatment of Non-Congenital Myotonic Dystrophy Type 1

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Steriles Manufacturing Site in Ridgefield, New Jersey of Sanofi (ENXTPA:SAN).

Sanofi Announces the Us Food and Drug Administration Approves Wayrilz (Rilzabrutinib) in US as First BTK Inhibitor for Immune Thrombocytopenia

Sanofi Confirms Earnings Guidance for the Year 2025

Sanofi's Sarclisa Approves in the EU for the Treatment of Transplant-Efficient Newly Diagnosed Multiple Myeloma

Sanofi Announces BEYFORTUS Reduced Hospital and Doctor Visits for RSV Disease in Babies by 87%

Sanofi (ENXTPA:SAN) entered into an agreement to acquire Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC for $1.6 billion.

Sanofi (ENXTPA:SAN) completed the acquisition of Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC.

Sanofi's Sar446597 Earns Fast Track Designation in the US for Geographic Atrophy Due Toage-Related Macular Debutation

Sanofi Announces Riliprubart Granted Orphan Drug Designation in Japan for Chronic Inflammative Demyelinating Polyneuropathy

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Sanofi Accelerates Global Shipping of Beyfortus to Prepare Healthcare Providers Months Ahead of 2025-2026 RSV Season

American Society of Clinical Oncology Announces New Sarclisa Data Support Subcutaneous Administration with On-Body Injector

Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Sanofi (ENXTPA:SAN) entered into a definitive merger agreement to acquire Vigil Neuroscience, Inc. (NasdaqGS:VIGL) for approximately $380 million.

Sanofi Appoints Clotilde Delbos as Chairwoman of the Compensation Committee